Data of relapsed patients both at diagnosis and at relapse.

<p>HP: erradication therapy; F: Fludarabine; Chemo: Chemotherapy.</p>*<p>Time to relapse in months.</p

Clinical characteristics of gastric MALT lymphoma patients at study entry.

<p>Clinical characteristics of gastric MALT lymphoma patients at study entry.</p

Immunohistochemistry by gastric condition (cells/mm²).

<p>MALT: mucosa-associated lymphoid tissue; DLBCL: diffuse large B-cell lymphoma; CG: chronic gastritis; HP: <i>Helicobacter pylori</i>.</p

Kinetics of CD3+, FOXP3+, ratio FOXP3+/CD3+ and CD20+ cells by immunohistochemistry in responding patients.

<p>Median CD20+ cells were significantly different between cases treated with antibioticis and those treated with fludarabine or bendamustine with or without Rituximab at first response evaluation (p = 0.001) but not later during follow-up.</p

Immunohistochemistry for CD20 and FOXP3 at study entry and at first response evaluation (1–2 months after finishing treatment).

<p>Gastric biopsies samples from 4 gastric MALT lymphoma patients treated with different schedules. HP: erradication therapy alone; RQ: Rituximab+CHOP; RF: Rituximab+Fludarabine; RB: Rituximab+Bendamustine.</p

Number and types of treatments followed by the patients included in the study.

<p>ND, not done.</p